Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
Sorry. No data so far.
Global Pharma US & EU Outlook 2015 : First –In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies
US$ 2000“Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition
10-19 2016 Pages: 63Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives
US$ 2000The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative. It pains most of the companies – whether generic or innovator. The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations.
10-19 2016 Pages: 153India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics
US$ 2000“Domestic sales improved in 2014, recovering from the slump in the 2013 caused by the market’s reaction to the new drug pricing policy. In 2015, growth is expected to continue to be healthy, as the momentum continues and improving economic growth allow more spending on healthcare.
10-19 2016 Pages: 109Biogen Idec – Poised to Grow Beyond MS
US$ 140BIIB’s efforts towards diversification are finally taking going to take shape from this year onwards with approvals of drugs in indications other than Multiple Sclerosis (MS) while BIIB’s supremacy in MS to remain. Positive new data from ELOCTATE (long-acting rec. Fact VIIIFc, hemophilia A) and ALPROLIX (long-acting rec. Fact IXFc, hemophilia B – Hemo B) presented at the XXIV ISTH Congress reinforces their advantages/potential safety, efficacy, and pharmacokinetic profile.
07-22 2015 Pages: 7Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 90DA recently issued a complete response letter to MRK’s Suvorexant. As per the complete response letter, the USFDA will need manufacturing data on the 10mg dose and clinical data for the 5mg dose. Due to safety concerns; the higher doses (30mg and 40mg) would not be approved.
07-22 2015 Pages: 1Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 800TAK-700 – No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed
07-22 2015 Pages: 14NATCO, Dismissal of Litigation over “Gad Patents” is Positive, Potential Launch Timing Still Contingent on Federal Circuit Outcome
US$ 90“US district court (NY Southern) granted a motion by Mylan and Sandoz to dismiss the litigation over 4 non OB patents (‘938, ‘802, ‘359 – expiring in Sept, 2019 and ‘580 – expiring in Feb – 2020). Together these patents are referred to as Gad Patents. The patents in suit claim polypeptide “markers” and methods of using such markers. Markers are polypeptides, when used with certain equipment, can measure the molecular weight of a sample of Glatiramer Acetate. The litigation has been dismissed as Mylan and Sandoz agreed not to use certain polypeptide markers to measure the weight of samples of Glatiramer Acetate.
07-22 2015 Pages: 1Merck – One timers and Forex weigh on Merck’s guidance
US$ 90MRK reported its 2Q 2013 results: the net sales decline by 11% ($11.0b) including negative foreign exchange impact by 3% compared to last year. Company reiterated its 2013 non-GAAP EPS guidance ($3.45 and $3.55) while revised its GAAP EPS to be between $1.84 and $2.05 (previous $1.92-2.16).
07-22 2015 Pages: 1Sanofi Q2-2013 Earnings – 2013 EPS Outlook trimmed
US$ 90Sanofi reported lower than expected 2Q-2013 financial results due to greater than anticipated impact of genericization, foreign exchange and write-off related to excessive inventory in Brazil. SAN has reduced its guidance and now assumes 7-10 percent decline in EPS as compared to 0-5 percent earlier.
07-22 2015 Pages: 3Novartis, 2013 Outlook revised but below expectations
US$ 90Novartis reported strong 2Q-2013 financial results due to the absence of Diovan generics in the US. For the same reason, Novartis has revised its earning guidance for the full year 2013. It now expects group net sales to grow at a low-single digit and the group core operating income to decline at a low-single digit rate.
07-22 2015 Pages: 3
